Shionogi & Co Ltd
TSE:4507
Net Margin
Shionogi & Co Ltd
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Net Margin Across Competitors
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| JP |
S
|
Shionogi & Co Ltd
TSE:4507
|
2.1T JPY |
39%
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
765.4B USD |
23%
|
|
| UK |
|
Dechra Pharmaceuticals PLC
LSE:DPH
|
440.4B GBP |
-4%
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
373.4B USD |
24%
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
2.2T DKK |
35%
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
209.1B CHF |
14%
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
188.8B CHF |
24%
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
167.7B GBP |
14%
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
203.7B USD |
27%
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
163.5B USD |
-126%
|
|
| US |
|
Pfizer Inc
NYSE:PFE
|
138.7B USD |
13%
|
Shionogi & Co Ltd
Glance View
In the bustling landscape of pharmaceuticals, Shionogi & Co., Ltd. emerges as a distinguished player with a rich legacy rooted in over a century of innovation and meticulous craftsmanship. Founded in 1878, this Japanese pharmaceutical stalwart has strategically steered its trajectory toward addressing unmet medical needs through research-driven innovation. Shionogi's core strength lies in its research and development capabilities, focusing predominantly on infectious diseases, pain therapeutics, and chronic conditions such as cardiovascular diseases and diabetes. This dedication is evident in their robust pipeline and successful launch of drugs like Fetroja—an antibiotic that fights resistant bacterial infections—and Xofluza, a novel anti-influenza medication. By continually investing in and prioritizing R&D, Shionogi ensures a steady output of groundbreaking treatments that not only embody therapeutic efficacy but also meet stringent safety standards. Financially, Shionogi operates through a strategic blend of innovative product sales and lucrative licensing agreements. As its proprietary medications penetrate global markets, the revenue stream flowing from these products fortifies the company’s economic foundation. Notably, Shionogi nurtures collaborative alliances with international pharmaceutical giants, enhancing its global outreach through mutual licensing agreements and shared drug development initiatives. These alliances not only expand the availability of its drugs worldwide but also provide Shionogi with substantial royalty and milestone payments. Additionally, the company's foray into vaccine production has further diversified its portfolio, as it aims to leverage its technological prowess in response to global health challenges. This intricate balance of direct product sales and strategic alliances powerfully anchors Shionogi's financial stability while paving the way for future innovations.
See Also
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Based on Shionogi & Co Ltd's most recent financial statements, the company has Net Margin of 38.9%.
You don't have any saved screeners yet